Menu Close

Mission Eliminate suffering, adverse societal impact and mortality caused by preventable, treatable diseases.

Vision Support good decision-making through verified epidemiological data, disease burden and economic impact modeling, intervention strategies, innovative financing, and knowledge-sharing partnerships.

STUDY. MODEL. IMPACT.

STUDY

CDA Foundation (CDAF) is a non-profit organization that specializes in the study of complex and poorly-understood diseases in order to provide countries/territories with the data and information to create and implement successful elimination strategies.

MODEL

The Polaris Observatory provides epidemiological data, modeling tools, training and decision analytics to support eliminating hepatitis B and C globally by 2030.

IMPACT

The Global Procurement Fund (GPRO) expands access to Hepatitis B and C diagnostics, medicines and HBV vaccines by supporting demonstration projects that provides evidence for effectiveness of simplified viral hepatitis elimination programs.

CDA Foundation does not have a job posting in Nigeria or any other country.  If you are being asked to transfer funds to apply for our job posting, it is a hoax.

Our Foundation’s Impact

CDA/CDAF’s history is marked by a series of innovative activities that have shaped the global hepatitis elimination efforts (read more)

Our Foundation in the News

Read what’s been written about CDAF and its work and how others have used CDAF’s data and expertise (read more)

Our Funding Sources

Our Collaborators

How Our Work Is Advancing Hepatitis Elimination Efforts

Case Study Brazil

CDAF collaborated with the Brazil Ministry of Health and Pan American Health Organization to develop a HCV elimination strategy which has now been implemented. In November 2017, Brazil announced its sustainable and financially viable plan to diagnose and treat all citizens infected with hepatitis C and eliminate the disease by 2030.

Case Study Egypt

CDAF partnered with the National Liver Institute in Egypt to develop economic analyses and strategies to eliminate HCV in Egypt. In 2016 alone, 577, 000 patients were treated and the plan expanded to include patients at all stages of disease. Egypt is now one of only 12 countries/territories on track to eliminate hepatitis C by 2030.

Case Study Mongolia

CDAF partnered with WHO’s Western Pacific Regional Office (WPRO) and the Mongolian Association on Study of Liver Diseases (MASLD) to model economic impact of HCV. The study showed that the HCV treated is cost-saving with a positive ROI. Mongolia is now one of only 12 countries/territories on track to eliminate hepatitis C by 2030.

Case Study Cameroon

CDAF partnered with the Cameroon Ministry of Health, The Pasteur Institute and the French Agency for Research on AIDS and Viral Hepatitis (ANRS) to model disease burden in Cameroon. The work revealed a much lower disease burden than previously reported. Work now focuses in modeling the economic impact of an expanded national HCV treatment program.

Projects Funded by CDA Foundation

Mozambique – HBV and HCV Disease Burden and Economic Impact

CDAF is working with the Mozambique MoH to update HBV and HCV disease burden and economic analyses and develop elimination strategies in support of the national Plan of Action and Guidelines.

Ukraine – HCV and HBV Disease Burden and National Elimination Strategy

CDA Foundation (CDAF) has been working closely with the World Health Organization (WHO EURO) over the past several years to identify the burden of HCV and HBV in Ukraine.

Brazil – HCV and HBV Disease Burden and National Elimination Strategy

Over the past two years, CDA Foundation (CDAF) has worked closely with the Brazilian Ministry of Health to analyze and develop management strategies for the hepatitis B and C disease burden at the national level.

Tibetan Population in India – HBV Disease Burden

CDA Foundation (CDAF), in collaboration with the Central Tibetan Authority (CTA), aimed to determine the current and future prevalence of chronic hepatitis B infection and identify the future public health impact of the disease.

Countries and Territories We Work With

Our Team

USFCR Verified Vendor
en_USEnglish